Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Stabilizing Iron-Sulfur Transport Clusters Reduces Size and Aggressiveness of Tumors

By LabMedica International staff writers
Posted on 21 Sep 2016
An international team of cancer researchers has identified a protein that, when overexpressed, enabled breast tumors to better withstand oxidative stress thereby becoming much larger and more aggressive.

The protein in question is the iron–sulfur (Fe-S) nutrient-deprivation autophagy factor-1 (NAF-1) protein, a member of the NEET family that transport clusters of iron and sulfur molecules inside cells. More...
The clusters, which adhere to the mitochondrial membrane, help regulate processes in cells by controlling reduction-oxidation (redox) and metabolic activity. NAF-1 is unique among Fe-S proteins due to its 3Cys-1His cluster coordination structure that allows it to be relatively stable, while still being able to transfer its clusters to apo-acceptor proteins.

Investigators at The Hebrew University of Jerusalem (Israel) and Rice University (Houston, TX, USA) reported in the September 12, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that overexpression of NAF-1 in xenograft breast cancer tumors resulted in a dramatic augmentation in tumor size and aggressiveness, and that NAF-1 overexpression enhanced the tolerance of cancer cells to oxidative stress.

The importance of NAF-1 overexpression was emphasized by the discovery of a NAF-1 mutant with a single point mutation that stabilized the NAF-1 clusters. The presence of the mutated form of the protein in xenograft breast cancer tumors resulted in a dramatic decrease in tumor size that was accompanied by enhanced mitochondrial iron and reactive oxygen accumulation and reduced cellular tolerance to oxidative stress. Treating breast cancer cells with pioglitazone, a compound that stabilized the 3Cys-1His cluster of NAF-1, resulted in a similar effect on mitochondrial iron and reactive oxygen species accumulation. This finding supports the potential use of drugs that suppress NAF-1 accumulation or stabilize its clusters for the treatment of cancers that display high expression levels of NAF-1.

Senior author Dr. Rachel Nechushtai, professor of biochemistry at The Hebrew University of Jerusalem, said, "Tumors depend on the lability, or the transient nature, of the clusters. The more NAF-1 you make, and the more its clusters can be transferred, the bigger the tumor develops. We knew from previous studies that pioglitazone stabilizes the cluster. With the mutant, we hardly got any tumors and did not see angiogenesis (the process through which new blood vessels form). When we did see tumors, they were white, not red, because they had no blood vessels."

"We thought, "How do we connect this to the clinics?" The only connection was to try a drug that, like the mutation, also stabilizes the cluster," said Dr. Nechushtai. "Dr. Fang Bai of Rice University showed in her simulations where the binding site is and why the drug stabilizes the cluster."

Related Links:
Hebrew University of Jerusalem
Rice University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.